Important Notice for Shareholders of Implantica AG
Implantica AG, reg. no. FL-0002.629.889-3, invites depository receipt holders to participate in the annual general meeting scheduled for May 15, with the location to be determined in the communication. This meeting is a significant opportunity for shareholders to engage with the company's direction and governance.
Participation Requirements
To attend the annual general meeting, interested parties must be listed as depository receipt holders in the Swedish Depository Receipt (SDR) register maintained by Euroclear Sweden. This registration must be completed by April 30. Shareholders are required to notify the company of their intent to attend by May 7, either via email or postal mail.
Proxy and Voting Information
Should shareholders choose to appoint a proxy, they must present a written power of attorney dated within one year before the meeting, along with any necessary authorization documents. For those unable to attend in person, voting can occur through mail by way of a designated Postal Voting Form, which should reach the custodian by the established deadline.
Key Agenda Items
The annual general meeting will feature a comprehensive agenda, including key proposals such as:
- Opening and appointment of the Chair of the meeting
- Approval of the minutes and agenda
- Presentation of the annual report and financial statements
- Discharge of the Board of Directors and management
- Voting on remuneration for board members
Financial Resolutions
One of the significant proposals includes the adoption of the statutory and consolidated financial statements, as well as resolutions regarding the financial results, which suggest no dividend payment for the last financial year due to losses. It is essential for shareholders to consider this aspect, as it directly impacts the financial health of the company moving forward.
Electronic Access to Documents
Complete proposals and documents, including auditor reports and accounting documents for 2024, will be accessible online and at the company’s headquarters. This transparency allows shareholders to prepare adequately before the meeting.
Additional Considerations
Shareholders are encouraged to submit questions regarding meeting items in advance via email. It showcases an approach of openness and engagement that Implantica AG promotes among its holders. Responses will be provided at the meeting if feasible.
About Implantica AG
Implantica AG is dedicated to developing advanced medical technology. The forefront offering, RefluxStop™, represents a newly established benchmark in treating gastroesophageal reflux, supported by strong clinical trial results. The company continues to innovate, focusing on eHealth solutions designed to improve health management through technology directly integrated into the body.
Frequently Asked Questions
When is the annual general meeting for Implantica AG?
The annual general meeting is scheduled for May 15.
How can I participate in the meeting?
Participation requires registration as a depository receipt holder and notification of attendance beforehand.
What is the financial situation of Implantica AG?
The company suggests carry-forward of the net loss for the financial year 2024, indicating no dividends this year.
Where can I find the meeting’s agenda?
The agenda will be included in the notice sent to shareholders and available through the company’s official communications.
How is personal data handled during the meeting process?
For details on personal data processing, please refer to the company's privacy notices.
